News

Funding cuts imperil cancer advances


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO Publicly funded research in oncology has great potential for reducing the costs of health care. Over the last 10 years, however, funding has dropped off appreciably.

In an exclusive interview at the annual meeting of the American Society of Clinical Oncology, Dr. Monica M. Bertagnolli, group chair of the Alliance for Clinical Trials in Oncology, discusses how cost-saving advances in oncology are being affected by the cut backs.

Recommended Reading

ACA still not reducing ranks of uninsured
MDedge Endocrinology
Know your values to achieve professional balance
MDedge Endocrinology
ACA understanding: The Policy & Practice Podcast
MDedge Endocrinology
Brand-drug costs rising faster than inflation
MDedge Endocrinology
AACE president shares advice with endocrinologists
MDedge Endocrinology
Tavenner confirmed as Medicare/Medicaid chief
MDedge Endocrinology
CMS offers $1 billion for health innovators
MDedge Endocrinology
EHR use reaches 'tipping point'
MDedge Endocrinology
CDC urges doctors to help patients quit smoking
MDedge Endocrinology
House Republicans proffer SGR fix legislation
MDedge Endocrinology